THD NewsDesk, New Delhi: Drug firm Zydus Cadila on Friday said it has received restricted emergency use approval from the Indian drug regulator for the use of Pegylated Interferon alpha-2b (PegIFN) in treating moderate Covid-19 infection in adults.
With the current shortage of vaccines and medicines, the company has received restricted emergency use approval from thee drug controller of India (DCGI) for the use of ‘Virafin’, PegIFN in treating moderate Covid-19 infection in adults.
PegIFN has very well-established safety with multiple doses in chronic Hepatitis B and C patients for many years.
Cadila Healthcare MD Sharvil Patel said
“The fact that we are able to offer a therapy which significantly reduces the viral load when given early on can help in better disease management. It comes at a much-needed time for patients and we will continue to provide them access to critical therapies in this battle against Covid-19.”
Shares of Cadila Healthcare, the listed entity of the Zydus Group, closed at Rs 571.20 per scrip on BSE, up 3.43 per cent from its previous close.
With time, the availability and accessibility of this drug will give prepare the country for a better fight hopefully.
Source: Times of India
